Purdue Pharma got sentenced this week, but nobody’s going to jail. According to reporting from the Associated Press, a federal judge handed down a criminal conviction against the OxyContin maker for what she called “a purposeful, intentional and sophisticated crime scheme.” The company will pay $225 million to the federal government, cease to exist by Friday, and transform into a new entity called Knoa Pharma. Members of the Sackler family, who own the company, committed to contributing up to $7 billion over 15 years. By most measures, this is the largest settlement in the opioid crisis reckoning so far.
And yet, in a courtroom where victims spent five hours describing how they lost children, siblings, and decades of their lives to addiction, the word “justice” kept getting swallowed by an uncomfortable silence.
A Crime Scheme Without Criminals
Here’s the thing that caught U.S. District Judge Madeline Cox Arleo’s attention, and should catch ours: Purdue Pharma admitted to lying to the DEA about its safeguards against black market diversion. The company admitted it paid doctors through a speakers program to prescribe OxyContin. It admitted to paying an electronic health records company to send doctors patient data designed to encourage more opioid prescriptions. These aren’t accidents or missteps. They’re calculated moves wrapped in corporate structure.
Yet not a single employee or owner faced criminal charges. The company pled guilty. The company got sentenced. But the humans who orchestrated the strategy? They remain untouched by criminal consequences.
Judge Arleo didn’t hold back on this point. She noted that she’s sentenced street-level drug dealers to prison for selling OxyContin, yet “those who started the epidemic will not serve a sentence.” The contrast isn’t subtle. It’s the kind of legal inequality that erodes faith in the system itself.
The Settlement Math Doesn’t Add Up
The numbers sound massive until you actually look at them. Purdue’s guilty plea involved $8.3 billion in forfeitures, fines, and penalties. But the federal government agreed to collect just $225 million. Why? Because Purdue reached a separate settlement covering thousands of lawsuits from states, local governments, Native American tribes, and other groups. That distinction matters because it splits the financial burden across multiple entities rather than concentrating accountability in one place.
The Sackler family will pay up to $7 billion over 15 years, not all at once. Judge Arleo spotted this immediately. “They’d rather pay it from future money than pay it now,” she observed dryly. When you can spread payments over 15 years, the annual impact on family finances becomes manageable. It’s the difference between a genuine financial consequence and a negotiated arrangement that stings less with each passing year.
Consider what didn’t happen: Purdue’s guilty plea included no restitution to victims. Individual victims and survivors are expected to receive between $8,000 and $16,000 each, a sum that barely registers against the catastrophic personal and financial damage described in court testimony. And many victims may not qualify at all because they can’t locate prescriptions from decades ago.
One mother, Alexis Pluis, lost her son to opioids in 2014 but can’t access 23-year-old medical records proving he was prescribed OxyContin. “We still deserve justice,” she said. “And this isn’t it.”
What Counts as Victory Here?
The settlement is genuinely the largest of its kind. More than $50 billion in total across all opioid-related settlements involving drugmakers, wholesalers, and pharmacies. Most of that money is supposed to go toward addressing the overdose epidemic. Purdue’s internal documents will be made public. The company’s name will effectively be erased, replaced by Knoa Pharma with a new board appointed by states and tasked with fighting the crisis it helped create.
And yes, there’s something symbolically important about forcing the Sackler family to agree not to object if their names are removed from museums and institutions they’ve funded. At least that acknowledgment exists.
But none of this undoes the core problem: a company engaged in systematic deception that contributed to an epidemic killing roughly 900,000 Americans since 1999, and the people responsible for that deception continue their lives without prison time. The judge heard victims describe children born into withdrawal and families torn apart. She kept photos of their lost loved ones, which she said she’ll display in her chambers for as long as she serves. That’s empathy from the bench, but empathy doesn’t compensate for the structural inequity at play.
The Uncomfortable Truth
What Tuesday’s hearing exposed isn’t a story about perfect justice finding its way through the system. It’s a story about a system that punishes companies and compensates victims with settlements, while the architects of harm negotiate their way through courtrooms largely intact. The judge herself pointed to the hypocrisy: street dealers get prison time for distributing the exact product that Purdue designed, marketed, and profited from.
This matters beyond the opioid crisis. It shapes how business operates in America when major corporations face criminal liability. It shows that even in the largest settlements, even with guilty pleas and dissolved companies, the personal accountability remains optional. The question isn’t whether Purdue Pharma will disappear or whether money will flow toward treatment programs. Those things will happen. The question is whether enough people noticed that nobody responsible for the scheme will actually face prison.
